Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 13c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $4.05 +1.00%
EPS Growth %: -78.9%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: -78.9%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.82), $0.13 worse than the analyst estimate of ($0.69). Revenue for the quarter came in at $51.72 million versus the consensus estimate of $55.04 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $258.2 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- First Bank (FRBA) Tops Q3 EPS by 5c
- CVB Financial (CVBF) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
